20.500.12556/DiRROS-18659 Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer Background. Trastuzumab therapy given in combination with one of several chemotherapy regimens is currently considered the standard of care for the treatment of early-stage, human epidermal growth factor receptor-2 (HER2) -positive breast cancer. The treatment with trastuzumab is due to a significant impact on the survival part of the standard adjuvant treatment of patients with HER2-positive breast cancer. Patients treated with postoperative breast or chest wall irradiation receive trastuzumab concomitant with radiotherapy. In a small proportion of patients trastuzumab causes cardiotoxicity. Preclinical findings indicate a radiosensibilizing effect of trastuzumab in breast cancer cells, but it is not yet clear whether it radiosensibilizes cells of healthy tissues too.Conclusions. Special attention is required when left breast or left thoracic wall is irradiated in patient receiving trastuzumab, because long-term effects of the concurrent treatment with trastuzumab and radiotherapy are not yet known. In an era where more patients are surviving a diagnosis of breast cancer, better understanding and earlier detection of therapy-induced cardiac toxicity will be of paramount importance. radiotherapy cardiotoxicity trastuzumab early breast cancer radioterapija kardiotoksičnost dojke rak (medicina) true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-04-11 10:55:33 2024-04-11 10:55:33 2024-04-12 03:37:21 0000-00-00 00:00:00 2014 0 0 str. 105-112, I no. 2 Vol. 48 Jun. 2014 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2014-06-01 618.19-006-08 1318-2099 10.2478/raon-2013-0040 1686139 http://www.degruyter.com/view/j/raon.2014.48.issue-2/raon-2013-0040/raon-2013-0040.xml?format=INT 1 7ea3e244-f7d0-11ee-ae20-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25489 RAZ_Marinko_Tanja_2014.pdf RAZ_Marinko_Tanja_2014.pdf 1 7CABEA8D7E59407DF48292569B1A815A 77e997ea904473c728901fcb4a4449f654e3d89828be36f9dde97487e6bc3f7a c208b7e2-f7d0-11ee-ae20-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25490 Onkološki inštitut Ljubljana 0 0 0